(ABM FN-Dow Jones) After a visit to a factory in the US of Philips, the US regulator FDA has not adjusted its opinion about the ventilators of the Dutch company, although a new problem was discovered. Jefferies analysts said this on Monday.
Philips recently paid a visit to the US regulator, FDA, at a factory in the US because of the recall of certain ventilators and presented the Dutch medtech company with a list of findings. This was reported by Philips last weekend.
The FDA has not revised its opinion on the ventilator, the analysts at Jefferies said, but did come up with a list of points. showing that procedures and risk analyzes were inadequate. Philips must be held accountable for this. A new security problem was also discovered.
Philips does not expect this to slow down the repair and replacement process, Jefferies said.
“The news isn’t positive for sentiment, but the market is already pricing in a recovery in sleep activity,” said Jefferies.
Jefferies has a buy recommendation on Philips with a price target of 52.00 euros. The share closed Friday at 41.71 euros.
Bron: ABM Financial News
–
From Beursplein 5, the editors of ABM Financial News keep a close eye on developments on the stock exchanges, and the Amsterdam stock exchange in particular. The information in this column is not intended as professional investment advice or as a recommendation to make certain investments.
